ESR1 and ovarian cancer: Although ERα positive malignancies are conventionally associated with improved prognosis and sensitivity to AET, exploitation of ERα as a treatment strategy has not gained wide acceptance in ovarian cancer care despite known expression of the receptor [9], [10].